Andrea K Miyahira1, Kenneth J Pienta2, John W Babich3, Neil H Bander4, Jeremie Calais5, Peter Choyke6, Michael S Hofman7,8, Steven M Larson9, Frank I Lin6, Michael J Morris10, Martin G Pomper2, Shahneen Sandhu7,11, Howard I Scher10,12, Scott T Tagawa13, Scott Williams7,14, Howard R Soule1. 1. Science Department, Prostate Cancer Foundation, Santa Monica, California. 2. Department of Urology, The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Radiology, Weill Cornell Medicine, New York, New York. 4. Laboratory of Urologic Oncology, Department of Urology and Meyer Cancer Center, Weill Cornell Medicine, New York, New York. 5. Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 6. Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 7. Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia. 8. Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia. 9. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 10. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 11. Department of Medical Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia. 12. Department of Medicine, Weill Cornell Medical College, New York, New York. 13. Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York. 14. Department of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia.
Abstract
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY. METHODS: The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer. RESULTS: Several major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT. DISCUSSION: This article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY. METHODS: The meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer. RESULTS: Several major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT. DISCUSSION: This article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.
Authors: Ronnie C Mease; Choong Mo Kang; Vivek Kumar; Sangeeta Ray Banerjee; Il Minn; Mary Brummet; Kathleen L Gabrielson; Yutian Feng; Andrew Park; Ana P Kiess; George Sgouros; Ganesan Vaidyanathan; Michael R Zalutsky; Martin G Pomper Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: Asim Afaq; Heather Payne; Reena Davda; John Hines; Gary J R Cook; Marie Meagher; Dimitrios Priftakis; Victoria S Warbey; Anand Kelkar; Clement Orczyk; Anita Mitra; Sarah Needleman; Michael Ferris; Greg Mullen; Jamshed Bomanji Journal: J Nucl Med Date: 2021-03-19 Impact factor: 11.082
Authors: Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova Journal: Pharmaceutics Date: 2021-01-30 Impact factor: 6.321
Authors: Srikanth Boinapally; Hye-Hyun Ahn; Bei Cheng; Mary Brummet; Hwanhee Nam; Kathleen L Gabrielson; Sangeeta R Banerjee; Il Minn; Martin G Pomper Journal: Sci Rep Date: 2021-03-29 Impact factor: 4.379
Authors: Sophie Bockhold; Shane J Foley; Louise A Rainford; Riccardo Corridori; Annika Eberstein; Christoph Hoeschen; Mark W Konijnenberg; Susan Molyneux-Hodgson; Graciano Paulo; Joana Santos; Jonathan P McNulty Journal: J Transl Med Date: 2022-03-18 Impact factor: 5.531